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cantly, only 2% had mild aortic
insufficiency. Comparison of these two se-
ries is difficult because of the differences in
population and etiology, but in the absence
of prospective or randomized studies, we
must base our decisions on extrapolation
from current data. Thus there is no conclu-
sive evidence that valve-sparing operations
for patients with MFS have an advantage
relative to Freestyle root replacement. Anti-
mineralization treatment and zero-pressure
fixation8 make this valve more attractive for
implantation than a homograft because of the
lower rate of calcification with no significant
changes in the elastic properties of the elastic
wall,8,9 and reoperation if needed is simpler
with the Freestyle bioprosthesis because of
lessened inflammatory reaction in the host
tissues. A Freestyle root replacement with
graft extension could be a reasonable opera-
tion for patients with MFS for whom antico-
agulation is contraindicated or not accept-
able. Further long term data are needed,
however, before any of these operations can
be recommended with certainty.
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Amiodarone for postoperative atrial
fibrillation
To the Editor:
We read with interest the article by Yagdi
and colleagues1 dealing with the use of
amiodarone to prevent of postoperative
atrial fibrillation (AF). In this prospective,
randomized study, 77 patients (amiodarone
group) received intravenous amiodarone
during the first 48 hours after the operation
followed by declining oral dosing over a
30-day period, and 80 patients (control
group) received placebo. The authors ob-
served a statistically significant reduction
in the incidence of AF (10% in amiodarone
group vs 25% in control group) as well as
a significant reduction in the mean duration
of AF (12.8  4.8 hours in amiodarone
group vs 34.7  28.7 hours in control
group).
We recently reported similar results in a
prospective, randomized study conducted
with 200 consecutive patients undergoing
CABG.2 The treatment group received oral
amiodarone 4 hours after arrival to the in-
tensive care unit and until hospital dis-
charge. The incidence of AF was reduced
from 25% to 12%, and its duration was also
reduced.
These two prospective randomized tri-
als constitute additional evidence for the
efficacy of amiodarone in the prevention of
AF after CABG. Interestingly, although in
our series only the oral form of amiodarone
was used, the results observed were almost
identical to those reported by Yagdi and
colleagues,1 suggesting that the intrave-
nous administration of amiodarone may not
offer additional beneficial effects in pre-
venting postoperative AF. If these observa-
tions were to be confirmed in future stud-
ies, the problem of the cost-effectiveness of
the use of amiodarone in this setting, as
alluded to in the editorial by Saltman,3
would be completely resolved.
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Reply to the Editor:
There is no consensus about the optimal
dose and route of amiodarone in prophy-
laxis against atrial fibrillation after coro-
nary artery bypass grafting. In most of the
studies we cited in our article,1 intravenous
amiodarone doses ranged from 10 mg/(kg ·
d) to 20 mg/(kg · d) through 2 to 8 days.
Oral amiodarone doses ranged from 2.8 to
7.0 g through 7 to 20 days. We used rela-
tively short-term, low-dose (10 mg/[kg · d],
for 48 hours) intravenous administration,
followed by oral tapered doses at a total of
9.0 g through 30 days. We prefer a combi-
nation therapy to take the advantage of
accelerated loading time with the intrave-
nous amiodarone and to obtain the incre-
mental benefits of the oral amiodarone
during the short-term intravenous adminis-
tration.
We found that the postoperative admin-
istration of amiodarone was effective at
significantly reducing the incidence of
postoperative atrial fibrillation by 14.6%,
the duration of atrial fibrillation episodes
by 21.9 hours, and the ventricular response
rate by 20 beats/min. In addition to the
lower incidence of postoperative atrial fi-
brillation, the amiodarone group had sig-
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